EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer

John V Heymach, David Harpole, Tetsuya Mitsudomi, Janis M Taube, Gabriella Galffy, Maximilian Hochmair, Thomas Winder, Ruslan Zukov, Gabriel Garbaos, Shugeng Gao, Hiroaki Kuroda, Gyula Ostoros und 16 weitere

New England Journal of Medicine · 02.11.2023 · 389 (18) · 1672-1684

DOI: 10.1056/nejmoa2304875 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 02.11.2023. Verfasst von John V Heymach und 27 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Thoracic-Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (J.V.H.), and US Oncology Re…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunological, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 810-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Agents, ImmunologicalCarcinoma, Non-Small-Cell LungLung NeoplasmsHumansAdjuvants, ImmunologicAdministration, IntravenousAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenCombined Modality TherapyNeoplasm Recurrence, LocalAntibodies, Monoclonal

Substanzen

Adjuvants, ImmunologicAntineoplastic Agents, ImmunologicalB7-H1 AntigendurvalumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • From the Department of Thoracic-Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (J.V.H.), and US Oncology Research, the Woodlands (A.S.) - both in Texas; the Department of Surger…

ORCID-Profile: Bivas Biswas

Förderung

  • AstraZeneca

Zitieren

APA

Heymach, J. V., Harpole, D., Mitsudomi, T., Taube, J. M., Galffy, G., Hochmair, M., Winder, T., Zukov, R., Garbaos, G., Gao, S., Kuroda, H., Ostoros, G., Tran, T. V., You, J., Lee, K. Y., Antonuzzo, L., Papai-Szekely, Z., Akamatsu, H., Biswas, B., …, & AEGEAN Investigators (2023). Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer. New England Journal of Medicine, 389(18), 1672-1684. https://doi.org/10.1056/nejmoa2304875

Vancouver

Heymach JV, Harpole D, Mitsudomi T, Taube JM, Galffy G, Hochmair M, et al. Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2023;389(18):1672-1684. doi:10.1056/nejmoa2304875

BibTeX
@article{Heymach2023,
  author = {Heymach, John V and Harpole, David and Mitsudomi, Tetsuya and Taube, Janis M and Galffy, Gabriella and Hochmair, Maximilian and Winder, Thomas and Zukov, Ruslan and Garbaos, Gabriel and Gao, Shugeng and Kuroda, Hiroaki and Ostoros, Gyula and Tran, Tho V and You, Jian and Lee, Kang-Yun and Antonuzzo, Lorenzo and Papai-Szekely, Zsolt and Akamatsu, Hiroaki and Biswas, Bivas and Spira, Alexander and Crawford, Jeffrey and Le, Ha T and Aperghis, Mike and Doherty, Gary J and Mann, Helen and Fouad, Tamer M and Reck, Martin and AEGEAN Investigators, AEGEAN Investigators},
  title = {Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {389},
  number = {18},
  pages = {1672--1684},
  doi = {10.1056/nejmoa2304875}
}
Kostenlos starten →